Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Pathogenic implications of iron accumulation in multiple sclerosis.
Interleukin-10 but not transforming growth factor-β1 gene expression is up-regulated by vitamin D treatment in multiple sclerosis patients.
Genentech and Biogen Idec announce top-line results from a Phase II/III clinical trial of Rituxan in primary-progressive multiple sclerosis
CSF levels of YKL-40 are increased in MS and replaces with immunosuppressive treatment.
Receptos to deliver scientific presentation at Digestive Disease Week 2012 about the therapeutic role of RPC1063 in inflammatory bowel disease
Chemokine-enhanced migration of human peripheral blood mononuclear cells is antagonized by interferon beta-1b through an effect on matrix metalloproteinase-9.
HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-β therapy in multiple sclerosis.
Extavia Prescribing Information
Masitinib in Patients with Progressive or Relapse-Free Secondary Multiple Sclerosis
Product Portfolio, Meda
Guillain-Barré Syndrome (42 Cases) Occurring During a Zika Virus Outbreak in French Polynesia.
Comprehensive Immunophenotyping of CSF cells in relapsing-remitting multiple sclerosis patients with daclizumb therapy
In vivo time-lapse imaging shows dynamic oligodendrocyte progenitor behavior during zebrafish development.
Benzothiazole and stilbene derivatives as promising PET myelin radiotracers for multiple sclerosis.
Posturography in MS patients treated with high dose methylprednisolone.
Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis.
Circulating innate lymphoid cells are unchanged in response to DAC HYP therapy.
Regenerative cellular therapies for neurologic diseases.
Comparative effectiveness of early Natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
Bioengineered cell culture systems of central nervous system injury and disease.
Multiple sclerosis: clinical presentation, diagnosis and treatment.
AB Science confirms the filing for the Marketing Authorization Application to the European Medicines Agency of masitinib in the treatment of pancreatic cancer
Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: A randomized clinical trial.
Interferon-β1a protects neurons against mitochondrial toxicity via modulation of STAT1 signaling: Electrophysiological evidence.

Pages